The Development and Content Validation of the Sjögren's Related Quality of Life Instrument (SRQoL).
Content validity
Health-related quality of life (HRQoL)
Instrument development
Patient-reported outcome (PRO)
Qualitative interviews
Sjögren’s
Journal
Rheumatology and therapy
ISSN: 2198-6576
Titre abrégé: Rheumatol Ther
Pays: England
ID NLM: 101674543
Informations de publication
Date de publication:
10 Oct 2024
10 Oct 2024
Historique:
received:
17
07
2024
accepted:
17
09
2024
medline:
11
10
2024
pubmed:
11
10
2024
entrez:
10
10
2024
Statut:
aheadofprint
Résumé
Several clinical outcome assessment (COA) instruments assess Sjögren's disease (Sjögren's) symptoms, but do not provide comprehensive assessment of the health-related quality of life (HRQoL) impact of Sjögren's. This study aimed to develop a patient-reported outcome (PRO) instrument for the assessment of HRQoL, intended for use in clinical trials and clinical practice in the assessment of treatment benefit. Review of study sponsor proprietary data and qualitative interviews informed the development of a conceptual model, the Sjögren's Related Quality of Life (SRQoL) and patient global impression of severity (PGI-S) and change (PGI-C) items. Combined concept elicitation and cognitive debriefing interviews with patients with Sjögren's explored their HRQoL impact experience and content validity of the SRQoL and PGI items. Twenty participants were interviewed about their Sjögren's experience. Following inductive analysis of interviews, concepts were categorized into eight domains: emotional well-being (e.g., worry and stress; n = 20/20; 100%), sleep (e.g., daytime sleepiness and waking up during the night; n = 20/20; 100%), activities of daily living (e.g., difficulty looking at screens and difficulty driving; n = 20/20; 100%), cognition (e.g., concentration difficulties and word finding difficulties; n = 19/20; 95.0%), physical functioning (e.g., difficulty walking and difficulty exercising; n = 19/20; 95.0%), social and family functioning (e.g., dependent on others and relationship difficulties; n = 17/20; 85.0%), work (n = 15/20; 75.0%), and sexual functioning (n = 12/20; 60.0%). SRQoL and PGI items, instructions, response options, and recall period were well understood and relevant to participants. The SRQoL is a new PRO instrument to assess Sjögren's impact on HRQoL, developed in accordance with regulatory guidance. This study provides considerable insight into the patient experience of Sjögren's and evidence to support the content validity of the SRQoL. Future research should evaluate the psychometric properties of the SRQoL to support its use in clinical trials and clinical practice and further validate its use as an assessment of treatment benefit. Patient and physician completed questionnaires used in clinical trials and clinical practice have previously focused on symptoms. These questionnaires do not cover the full experience of living with Sjögren’s, such as differences in symptoms between individual patients, and their use has also been known to result in inaccurate reports. Another way of thinking about patients’ experiences is to use a questionnaire to ask about the impact Sjögren’s has on patients’ health-related quality of life, meaning how Sjögren’s might affect their life in different ways including physically, emotionally, and socially. The goal of this study was to develop a new questionnaire (named the Sjögren’s-Related Quality of Life [SRQoL] questionnaire) to measure the impact that Sjögren’s has on patients’ lives. Interviews were conducted with people with Sjögren’s to explore their understanding of the new questionnaire and how relevant the content is to their experience of the condition. The results of this study suggest that the SRQoL includes relevant and easy-to-understand questions, suitable for use in future clinical trials and clinical practice, to measure if patients’ HRQoL improves with treatment. Future research is needed to confirm that the questionnaire accurately measures the impact of Sjögren’s on HRQoL for use with patients with Sjögren’s.
Autres résumés
Type: plain-language-summary
(eng)
Patient and physician completed questionnaires used in clinical trials and clinical practice have previously focused on symptoms. These questionnaires do not cover the full experience of living with Sjögren’s, such as differences in symptoms between individual patients, and their use has also been known to result in inaccurate reports. Another way of thinking about patients’ experiences is to use a questionnaire to ask about the impact Sjögren’s has on patients’ health-related quality of life, meaning how Sjögren’s might affect their life in different ways including physically, emotionally, and socially. The goal of this study was to develop a new questionnaire (named the Sjögren’s-Related Quality of Life [SRQoL] questionnaire) to measure the impact that Sjögren’s has on patients’ lives. Interviews were conducted with people with Sjögren’s to explore their understanding of the new questionnaire and how relevant the content is to their experience of the condition. The results of this study suggest that the SRQoL includes relevant and easy-to-understand questions, suitable for use in future clinical trials and clinical practice, to measure if patients’ HRQoL improves with treatment. Future research is needed to confirm that the questionnaire accurately measures the impact of Sjögren’s on HRQoL for use with patients with Sjögren’s.
Identifiants
pubmed: 39388050
doi: 10.1007/s40744-024-00718-6
pii: 10.1007/s40744-024-00718-6
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
© 2024. The Author(s).
Références
Shiboski S, Shiboski C, Criswell L, et al. ACR classification criteria for Sjögren’s syndrome: a data-driven, expert consensus approach in the Sjögren’s International Collaborative Clinical Alliance cohort. Arthritis Care Res. 2012;64(4):475–87.
Patel R, Shahane A. The epidemiology of Sjögren’s syndrome. Clin Epidemiol. 2014;6:247.
pubmed: 25114590
pmcid: 4122257
Bowman SJ. Patient-reported outcomes including fatigue in primary Sjögren’s syndrome. Rheum Dis Clin N Am. 2008;34(4):949–62.
Stefanski A-L, Tomiak C, Pleyer U, Dietrich T, Burmester GR, Dörner T. The diagnosis and treatment of Sjögren’s syndrome. Deutsches arzteblatt Int. 2017;114(20):354.
Hammitt KM, Naegeli AN, van den Broek RW, Birt JA. Patient burden of Sjögren’s: a comprehensive literature review revealing the range and heterogeneity of measures used in assessments of severity. Rheum Musculoskelet Dis Open. 2017;3(2):e000443.
Seror R, Ravaud P, Mariette X, et al. EULAR Sjögren’s syndrome patient reported index (ESSPRI): development of a consensus patient index for primary Sjögren’s syndrome. Ann Rheum Dis. 2011;70(6):968–72.
pubmed: 21345815
Seror R, Theander E, Brun JG, et al. Validation of EULAR primary Sjögren’s syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). Ann Rheum Dis. 2015;74(5):859–66.
pubmed: 24442883
Seror R, Gottenberg J, Devauchelle-Pensec V, et al. EULAR Sjögren’s syndrome disease activity index (ESSDAI) and EULAR Sjögren’s syndrome patient-reported index (ESSPRI): a complete picture of primary Sjögren’s syndrome patients. Arthritis Care Res. 2013;65(8):1358–64.
Ndife B, Fenel S, Lewis S, Agashivala N. Development of a symptom diary for use in patients with Sjogren’s syndrome [abstract]. Arthritis Rheumatol. 2021;73.
Seror R, Baron G, Camus M, et al. Development and preliminary validation of the Sjögren’s Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sjögren’s syndrome. Ann Rheum Dis. 2022;81(7):979–89.
pubmed: 35393271
Arends S, de Wolff L, van Nimwegen JF, et al. Composite of relevant endpoints for Sjögren’s syndrome (CRESS): development and validation of a novel outcome measure. Lancet Rheumatol. 2021;3(8):e553–62.
pubmed: 38287621
Brito-Zeron P, Kostov B, Solans R, et al. Systemic activity and mortality in primary Sjögren syndrome: predicting survival using the EULAR-SS disease activity index (ESSDAI) in 1045 patients. Ann Rheum Dis. 2016;75(2):348–55.
pubmed: 25433020
Cornec D, Devauchelle-Pensec V, Mariette X, et al. Severe health-related quality of life impairment in active primary Sjögren’s syndrome and patient-reported outcomes: data from a large therapeutic trial. Arthritis Care Res. 2017;69(4):528–35.
Meiners P, Arends S, Brouwer E, Spijkervet F, Vissink A, Bootsma H. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren’s syndrome treated with rituximab. Ann Rheum Dis. 2012;71(8):1297–302.
pubmed: 22258489
Moerman RV, Arends S, Meiners PM, et al. EULAR Sjögren’s syndrome disease activity index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial. Ann Rheum Dis. 2014;73(2):472–4.
pubmed: 23940214
Quartuccio L, Salvin S, Fabris M, et al. BLyS upregulation in Sjögren’s syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands. Rheumatology. 2013;52(2):276–81.
pubmed: 22879463
Seror R, Bootsma H, Saraux A, et al. Defining disease activity states and clinically meaningful improvement in primary Sjögren’s syndrome with EULAR primary Sjögren’s syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). Ann Rheum Dis. 2016;75(2):382–9.
pubmed: 25480887
van der Heijden EHM, Blokland SLM, Hillen MR, et al. Leflunomide–hydroxychloroquine combination therapy in patients with primary Sjögren’s syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial. Lancet Rheumatol. 2020;2(5):e260–9.
pubmed: 38273473
Griffiths N, Wratten S, Flynn J, et al. Content validity of Sjögren’s syndrome symptom diary and functional assessment of chronic illness therapy-fatigue in patients with Sjögren’s. Rheumatol Ther. 2022;9(6):1559–74.
pubmed: 36152275
pmcid: 9561476
Tsuboi H, Hagiwara S, Asashima H, et al. Comparison of performance of the 2016 ACR-EULAR classification criteria for primary Sjögren’s syndrome with other sets of criteria in Japanese patients. Ann Rheum Dis. 2017;76(12):1980–5.
pubmed: 28330998
Li L, Cui Y, Chen S, Zhao Q, Gu Z. AB0513 Fatigue in Chinese patients with primary Sjögren’s syndrome: a cross sectional study. Br Med J. 2017.
Gottenberg J-E, Ravaud P, Puéchal X, et al. Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial. JAMA. 2014;312(3):249–58.
pubmed: 25027140
Mariette X, Ravaud P, Steinfeld S, et al. Inefficacy of infliximab in primary Sjögren’s syndrome: results of the randomized, controlled trial of remicade in primary Sjögren’s syndrome (TRIPSS). Arthritis Rheumatol. 2004;50(4):1270–6.
Miyamoto ST, Valim V, Fisher BA. Health-related quality of life and costs in Sjögren’s syndrome. Rheumatology. 2021;60(6):2588–601.
pubmed: 30770918
Perella C, Steenackers M, Robbins B, et al. Patient experience of Sjögren’s disease and its multifaceted impact on patients’ lives. Rheumatol Ther. 2023;10(3):601–14.
pubmed: 36797434
pmcid: 10140221
Seghieri C, Lupi E, Tzioufas AG, De Vita S, Baldini C. Patient-reported experience and health-related quality of life in patients with primary Sjögren’s syndrome in Europe. Clin Exp Rheumatol. 2021;39(6):S123–30.
Lackner A, Ficjan A, Stradner MH, et al. It’s more than dryness and fatigue: the patient perspective on health-related quality of life in primary Sjögren’s syndrome—a qualitative study. PLoS ONE. 2017;12(2):e0172056.
pubmed: 28182787
pmcid: 5300216
Kiltz U, van der Heijde D, Cieza A, et al. Developing and validating an index for measuring health in patients with ankylosing spondylitis. Rheumatology. 2011;50(5):894–8.
pubmed: 21156668
The EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199–208.
Lendrem D, Mitchell S, McMeekin P, et al. Health-related utility values of patients with primary Sjögren’s syndrome and its predictors. Ann Rheum Dis. 2014;73(7):1362–8.
pubmed: 23761688
Brazier JE, Harper R, Jones N, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ. 1992;305(6846):160–4.
pubmed: 1285753
pmcid: 1883187
Rostron J, Rogers S, Longman L, Kancy S, Field EA. Health-related quality of life in patients with primary Sjögren's syndrome and xerostomia: a comparative study. Gerodontology. 2002;19(1):53–9.
pubmed: 12164241
Tarn J, Lendrem D, McMeekin P, Lendrem C, Hargreaves B, Ng WF. Primary Sjögren’s syndrome: longitudinal real-world, observational data on health-related quality of life. J Intern Med. 2022;291(6):849–55.
pubmed: 35018685
pmcid: 9305875
Lackner A, Stradner MH, Hermann J, et al., editors. Assessing health-related quality of life in primary Sjögren’s syndrome—the PSS-QoL. Semin Arthritis Rheum. 2018;48(1):105–110.
Norquist JM, Girman C, Fehnel S, DeMuro-Mercon C, Santanello N. Choice of recall period for patient-reported outcome (PRO) measures: criteria for consideration. Qual Life Res. 2012;21:1013–20.
pubmed: 21909804
Food and Drug Administration. Patient-focused drug development: methods to identify what is important to patients. 2022. https://www.fda.gov/media/131230/download . Accessed June 2024.
Shiboski CH, Shiboski SC, Seror R, et al. 2016 ACR-EULAR classification criteria for primary Sjögren’s syndrome: a consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheumatol. 2017;69(1):35.
pubmed: 27785888
Izmirlym PM, Buyon JP, Wan I, et al. The incidence and prevalence of adult primary Sjögren’s syndrome in New York county. Arthritis Care Res. 2019;71(7):949–60.
Food and Drug Administration. Patient-focused drug development: collecting comprehensive and representative input. 2018. https://www.fda.gov/media/139088/download . Accessed June 2024.
Francis JJ, Johnston M, Robertson C, et al. What is an adequate sample size? Operationalising data saturation for theory-based interview studies. Psychol Health. 2010;25(10):1229–45.
pubmed: 20204937
Guest G, Bunce A, Johnson L. How many interviews are enough? An experiment with data saturation and variability. Field Methods. 2006;18(1):59–82.
Lamoureux R, Shields A, Stokes J, Yaworsky A, Galipeau N. How many subjects are enough for symptom-focused concept elicitation studies? A retrospective analysis of saturation across twenty-six studies. Value Health. 2015;18(3):A33.
Willis GB. Cognitive interviewing: a tool for improving questionnaire design. London: Sage; 2004.
Food and Drug Administration. Patient-focused drug development: Selecting, developing, or modifying fit-for-purpose clinical outcome assessments. 2022. https://www.fda.gov/media/159500/download . Accessed June 2024.
Food and Drug Administration. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. 2009. https://www.fda.gov/downloads/drugs/guidances/ucm193282.pdf . Accessed June 2024.
ATLAS.ti. Scientific software development GmbH [ATLAS.ti 22 Windows]. 2022. https://atlasti.com .
Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77–101.
Joffe H, Yardley L. Content and thematic analysis. In: Marks DF, Yardley L, editors. Research methods for clinical and health psychology. SAGE Publications; 2003. pp. 56–68.
World Medical Association. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. Bull World Health Org. 2001;79(4):373.
Food and Drug Administration. Regulations: good clinical practice and clinical trials. 2021. https://www.fda.gov/science-research/clinical-trials-and-human-subject-protection/regulations-good-clinical-practice-and-clinical-trials . Accessed June 2024.
European Medicines Agency. Good clinical practice—scientific guideline. 2016. https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-good-clinical-practice-e6r2-step-5_en.pdf . Accessed June 2024.
Vandenbroucke JP, Elm EV, Altman DG, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. Ann Intern Med. 2007;147(8):W-163-W−94.
Palm Ø, Garen T, Berge Enger T, et al. Clinical pulmonary involvement in primary Sjögren’s syndrome: prevalence, quality of life and mortality—a retrospective study based on registry data. Rheumatology. 2013;52(1):173–9.
pubmed: 23192906
Greenhalgh J. The applications of PROs in clinical practice: what are they, do they work, and why? Qual Life Res. 2009;18:115–23.
pubmed: 19105048
Brandt JE, Priori R, Valesini G, Fairweather D. Sex differences in Sjögren’s syndrome: a comprehensive review of immune mechanisms. Biol Sex Differ. 2015;6:1–13.
Reilly M, Bracco A, Ricci JF, Santoro J, Stevens T. The validity and accuracy of the work productivity and activity impairment questionnaire–irritable bowel syndrome version (WPAI: IBS). Aliment Pharmacol Ther. 2004;20(4):459–67.
pubmed: 15298641